APA (7th ed.) Citation

Tombal, B., Smith, M., Hussain, M., Saad, F., Fizazi, K., Sternberg, C., . . . Rezazadeh Kalebasty, A. (2023). A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS. European Urology, 83, S1709. https://doi.org/10.1016/S0302-2838(23)01222-8

Chicago Style (17th ed.) Citation

Tombal, B., et al. "A1184 - Tolerability and Pharmacokinetic Analyses of Combination Therapy with Darolutamide (DARO), Androgen-deprivation Therapy (ADT), and Docetaxel (DOC) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) from ARASENS." European Urology 83 (2023): S1709. https://doi.org/10.1016/S0302-2838(23)01222-8.

MLA (9th ed.) Citation

Tombal, B., et al. "A1184 - Tolerability and Pharmacokinetic Analyses of Combination Therapy with Darolutamide (DARO), Androgen-deprivation Therapy (ADT), and Docetaxel (DOC) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) from ARASENS." European Urology, vol. 83, 2023, p. S1709, https://doi.org/10.1016/S0302-2838(23)01222-8.